Due to delayed cancer medicine, Bristol Myers will be sued for $6.4 billion
A U.S. judge refuses to dismiss a $6.4 billion lawsuit against Bristol Myers Squibb. Trustee says drugmaker delayed cancer drug approval to avoid payments to shareholders. Former Celgene Corp was bought by Bristol Myers in 2019 for $80.3 billion. A U.S. judge on Friday would not excuse a $6.4 billion claim blaming Bristol Myers Squibb … Read more